Literature DB >> 19715548

Functional, global and cognitive decline correlates to accumulation of Alzheimer's pathology in MCI and AD.

M N Sabbagh1, K Cooper, J DeLange, J D Stoehr, K Thind, T Lahti, B Reisberg, L Sue, L Vedders, S R Fleming, T G Beach.   

Abstract

BACKGROUND: Cognitive, global and functional instruments have been extensively investigated for correlations with neuropathological changes such as neurofibrillary tangles (NFTs), plaques, and synapse loss in the brain.
OBJECTIVE: Our objective is to correlate the functional, global and cognitive decline assessed clinically with the neuropathological changes observed in a large prospectively characterized cohort of mild cognitive impairment (MCI) and Alzheimer's disease (AD).
METHODS: We examined 150 subjects (16 MCI and 134 AD) that were prospectively assessed and longitudinally followed to autopsy. MCI subjects clinically met Petersen criteria for single or multi-domain amnestic MCI. AD subjects clinically met NINCDS-ADRDA criteria for probable or possible AD. All subjects received the Functional Assessment Staging (FAST), the Global Deterioration Scale (GDS), and the Mini Mental State Examination (MMSE) ante-mortem. Plaque and tangle counts were gathered for hippocampus, entorhinal cortex, frontal, temporal and parietal cortices. Braak staging was performed as well.
RESULTS: The GDS, FAST and MMSE correlated with plaque counts in all regions. The GDS, FAST and MMSE correlated with tangle counts in in all regions. The three instruments also correlated with the Braak score. The MMSE and GDS correlate better than the FAST in most regions.
CONCLUSIONS: Accumulation of neuropathology appears to correlate with functional, global, and cognitive decline as people progress from MCI through AD.

Entities:  

Mesh:

Year:  2010        PMID: 19715548      PMCID: PMC3138789          DOI: 10.2174/156720510791162340

Source DB:  PubMed          Journal:  Curr Alzheimer Res        ISSN: 1567-2050            Impact factor:   3.498


  44 in total

1.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician.

Authors:  M F Folstein; S E Folstein; P R McHugh
Journal:  J Psychiatr Res       Date:  1975-11       Impact factor: 4.791

2.  The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease.

Authors:  S S Mirra; A Heyman; D McKeel; S M Sumi; B J Crain; L M Brownlee; F S Vogel; J P Hughes; G van Belle; L Berg
Journal:  Neurology       Date:  1991-04       Impact factor: 9.910

3.  The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects.

Authors:  G Blessed; B E Tomlinson; M Roth
Journal:  Br J Psychiatry       Date:  1968-07       Impact factor: 9.319

4.  Diagnosis of Alzheimer's disease.

Authors:  Z S Khachaturian
Journal:  Arch Neurol       Date:  1985-11

Review 5.  Dementia staging in chronic care populations.

Authors:  B Reisberg; S G Sclan; E Franssen; A Kluger; S Ferris
Journal:  Alzheimer Dis Assoc Disord       Date:  1994       Impact factor: 2.703

6.  Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease.

Authors:  G McKhann; D Drachman; M Folstein; R Katzman; D Price; E M Stadlan
Journal:  Neurology       Date:  1984-07       Impact factor: 9.910

7.  The Global Deterioration Scale for assessment of primary degenerative dementia.

Authors:  B Reisberg; S H Ferris; M J de Leon; T Crook
Journal:  Am J Psychiatry       Date:  1982-09       Impact factor: 18.112

8.  Clinico-pathologic studies in dementia: nondemented subjects with pathologically confirmed Alzheimer's disease.

Authors:  H Crystal; D Dickson; P Fuld; D Masur; R Scott; M Mehler; J Masdeu; C Kawas; M Aronson; L Wolfson
Journal:  Neurology       Date:  1988-11       Impact factor: 9.910

9.  Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop.

Authors:  G C Román; T K Tatemichi; T Erkinjuntti; J L Cummings; J C Masdeu; J H Garcia; L Amaducci; J M Orgogozo; A Brun; A Hofman
Journal:  Neurology       Date:  1993-02       Impact factor: 9.910

10.  Neurofibrillary tangles mediate the association of amyloid load with clinical Alzheimer disease and level of cognitive function.

Authors:  David A Bennett; Julie A Schneider; Robert S Wilson; Julia L Bienias; Steven E Arnold
Journal:  Arch Neurol       Date:  2004-03
View more
  33 in total

Review 1.  Cognition and neuropathology in aging: multidimensional perspectives from the Rush Religious Orders Study and Rush Memory And Aging Project.

Authors:  S Negash; D A Bennett; R S Wilson; J A Schneider; S E Arnold
Journal:  Curr Alzheimer Res       Date:  2011-06       Impact factor: 3.498

2.  Neuroimaging correlates with neuropathologic schemes in neurodegenerative disease.

Authors:  Val J Lowe; Emily S Lundt; Sabrina M Albertson; Scott A Przybelski; Matthew L Senjem; Joseph E Parisi; Kejal Kantarci; Bradley Boeve; David T Jones; David Knopman; Clifford R Jack; Dennis W Dickson; Ronald C Petersen; Melissa E Murray
Journal:  Alzheimers Dement       Date:  2019-06-04       Impact factor: 21.566

3.  Combined treatment with the phenolics (-)-epigallocatechin-3-gallate and ferulic acid improves cognition and reduces Alzheimer-like pathology in mice.

Authors:  Takashi Mori; Naoki Koyama; Jun Tan; Tatsuya Segawa; Masahiro Maeda; Terrence Town
Journal:  J Biol Chem       Date:  2018-12-18       Impact factor: 5.157

Review 4.  [Pathogenesis and prevention of Alzheimer's disease: when and in what way does the pathological process begin?].

Authors:  H Braak; S Feldengut; K Del Tredici
Journal:  Nervenarzt       Date:  2013-04       Impact factor: 1.214

5.  Widespread brain tau and its association with ageing, Braak stage and Alzheimer's dementia.

Authors:  Val J Lowe; Heather J Wiste; Matthew L Senjem; Stephen D Weigand; Terry M Therneau; Bradley F Boeve; Keith A Josephs; Ping Fang; Mukesh K Pandey; Melissa E Murray; Kejal Kantarci; David T Jones; Prashanthi Vemuri; Jonathan Graff-Radford; Christopher G Schwarz; Mary M Machulda; Michelle M Mielke; Rosebud O Roberts; David S Knopman; Ronald C Petersen; Clifford R Jack
Journal:  Brain       Date:  2018-01-01       Impact factor: 13.501

6.  Is it time to rethink how neuropsychological tests are used to diagnose mild forms of HIV-associated neurocognitive disorders? Impact of false-positive rates on prevalence and power.

Authors:  Ana-Claire L Meyer; W John Boscardin; Judith K Kwasa; Richard W Price
Journal:  Neuroepidemiology       Date:  2013-10-23       Impact factor: 3.282

Review 7.  Solid-state NMR studies of amyloid fibril structure.

Authors:  Robert Tycko
Journal:  Annu Rev Phys Chem       Date:  2011       Impact factor: 12.703

8.  Dementia induces correlated reductions in white matter integrity and cortical thickness: a multivariate neuroimaging study with sparse canonical correlation analysis.

Authors:  Brian B Avants; Philip A Cook; Lyle Ungar; James C Gee; Murray Grossman
Journal:  Neuroimage       Date:  2010-01-18       Impact factor: 6.556

9.  Gallic acid is a dual α/β-secretase modulator that reverses cognitive impairment and remediates pathology in Alzheimer mice.

Authors:  Takashi Mori; Naoki Koyama; Tomotaka Yokoo; Tatsuya Segawa; Masahiro Maeda; Darrell Sawmiller; Jun Tan; Terrence Town
Journal:  J Biol Chem       Date:  2020-09-10       Impact factor: 5.157

10.  Parkin prevents cortical atrophy and Aβ-induced alterations of brain metabolism: ¹³C NMR and magnetic resonance imaging studies in AD models.

Authors:  Norah Algarzae; Michaeline Hebron; Matthew Miessau; Charbel E-H Moussa
Journal:  Neuroscience       Date:  2012-09-06       Impact factor: 3.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.